Curated News
By: NewsRamp Editorial Staff
June 18, 2025
Psyence Biomed's Leader to Speak at Premier Psychedelic Science Event
TLDR
- Psyence Biomed's Chief of Global Impact speaking at PS2025 highlights the company's leadership in psychedelic research, offering a competitive edge in biopharma innovation.
- Psyence Biomed will present on business ethics at PS2025, detailing their approach to integrating profit with purpose in psychedelic medicine development.
- Psyence Biomed's focus on nature-derived psilocybin medicine aims to improve mental health care, making tomorrow better for patients with unmet needs.
- Discover how Psyence Biomed merges psychedelics and science to pioneer FDA-approved treatments, a groundbreaking approach in mental health therapy.
Impact - Why it Matters
This news highlights the growing recognition of psychedelic medicine's potential in addressing mental health issues, particularly in palliative care. Psyence Biomed's participation in PS2025 underscores the importance of ethical business practices in the burgeoning psychedelic sector. For individuals suffering from mental health disorders and those invested in the future of psychedelic therapies, this represents a significant step toward accessible, nature-derived treatments.
Summary
Psyence Biomed (NASDAQ: PBM), a leader in the development of nature-derived psychedelic medicines, has announced that its Chief of Global Impact, Mary-Elizabeth Gifford, will be a featured speaker at Psychedelic Science 2025 (PS2025). This event, hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), is the largest international conference dedicated to psychedelic research and culture. Gifford will participate in a panel titled "We are the Guardrails: Profit with Purpose," discussing business ethics in the psychedelic sector. Psyence Biomed stands out as the first Nasdaq-listed biopharma company focusing on non-synthetic psilocybin for FDA approval, aiming to meet unmet mental health needs, especially in palliative care.
For more details, the full press release can be viewed at https://ibn.fm/qr93E. Psyence Biomed's innovative approach combines psychedelics and science to develop safe, effective treatments for mental health disorders. Learn more about their groundbreaking work at www.PsyenceBiomed.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Psyence Biomed's Leader to Speak at Premier Psychedelic Science Event
